Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.
Business/Financial News
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
Private equity firms swap Sterigenics for $675 million | Acquisitions roundup
Sterigenics International Inc. is changing private equity ownership for $675 million.
Chicago-based firm GTCR LLC entered into a deal to buy the sterilization and ionization services company from fellow Chicagoans PPM America Capital Partners and Europe-based Silverfleet Capital.
The companies expect the deal to close by the end of the second quarter of 2011.
HeartWare’s Q4 sales blossom, losses surge
International markets were good to HeartWare International Inc. (NSDQ:HTWR) during the fourth quarter and full-year 2010, as the company posted large top-line increases, but the heart pump maker’s bottom-line gap widened as it spent to shepherd one device through the Food & Drug Administration and prepped another for animal studies.
Study: Higher risk of PTSD in women linked to stress hormones
Bruker breaks annual sales record in spite of lower Q4 profits | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Forest Labs to purchase Clinical Data for $1.2 billion | Acquisitions roundup
Forest Laboratories Inc. (NYSE:FRX) is planning a $1.2 billion takeover of Clinical Data Inc. (NSDQ:CLDA).
Under the terms of the merger agreement between the two companies, Forest Labs will pay $30 per share in cash, with additional milestone payments of up to $6 per share based on the commercial success of Clinical Data’s new antidepressant drug, Viibryd, according to the companies.
Fresenius guides 2011 revenues above the Street, but misses on bottom-line call
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is getting a small boost this side of the pond, with traders adding about 0.2% to its share price today in modest trading volume after the company forecast 6 percent to 8 percent revenue growth in 2011.
That topped the $12.74 billion average of nine analyst polled by Zacks by at least $60 million this year. Fresenius said earlier today it expects revenue to grow to a range between $12.8 billion to $13.0 billion.
For biotech investors, late-stage clinical trial failures no longer an option
The CED Biotech/Life Science Conference in Raleigh, N.C. closed with the engaging and entertaining story of MedImmune LLC, the Maryland biotechnology company that was acquired by AstraZeneca plc (NYSE:AZN) for $15.6 billion in 2007.
UBS raises Stryker to Buy from Neutral
Stryker Corp. (NYSE:SYK) shares are down slightly this afternoon despite a reported upgrade of the stock by UBS from Neutral to Buy.
The UBS analysts also raised their price target for the medical device manufacturer to $70.00 from $62.00, suggesting a potential 13.3 percent gain based on SYK’s current price of $61.85 a share.
Quest, LabCorp resist general stock slide
Gore wins European approval for vascular graft | Regulatory roundup
Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.